Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.35 |
| ▸ | USP19 | O94966 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041819 | 0.84 | CCR5 (0.37) | CCR5USP19MEN1KMT2AALDH1A1 | |
| SCHEMBL1800500 | 0.83 | MEN1 (0.41) | CCR5MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3917759 | 0.83 | NPSR1 (0.39) | CCR5USP19MEN1KMT2AALDH1A1 | |
| SCHEMBL1801173 | 0.81 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1798595 | 0.80 | LMNA (0.46) | USP19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1800968 | 0.80 | CYP3A4 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1798796 | 0.78 | KMT2A (0.37) | USP19MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3928453 | 0.77 | KDM4E (0.36) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1800768 | 0.77 | KMT2A (0.43) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1801813 | 0.77 | CYP2C9 (0.49) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | claimed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | CCR5 2852/4885USP19 1715/4885MEN1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.